Learn More About the PROSERA Study
Now enrolling: The PROSERA phase 3 study of seralutinib in adults with pulmonary arterial hypertension.
Seralutinib Treatment in Adult Subjects With Pulmonary Arterial Hypertension: Results From the TORREY Study (Presentation)